BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 36765089)

  • 1. Loss of phosphatase CTDNEP1 potentiates aggressive medulloblastoma by triggering MYC amplification and genomic instability.
    Luo Z; Xin D; Liao Y; Berry K; Ogurek S; Zhang F; Zhang L; Zhao C; Rao R; Dong X; Li H; Yu J; Lin Y; Huang G; Xu L; Xin M; Nishinakamura R; Yu J; Kool M; Pfister SM; Roussel MF; Zhou W; Weiss WA; Andreassen P; Lu QR
    Nat Commun; 2023 Feb; 14(1):762. PubMed ID: 36765089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
    Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
    J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An animal model of MYC-driven medulloblastoma.
    Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
    Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of Rb and p53 delays cerebellar development and predisposes to large cell anaplastic medulloblastoma through amplification of N-Myc and Ptch2.
    Shakhova O; Leung C; van Montfort E; Berns A; Marino S
    Cancer Res; 2006 May; 66(10):5190-200. PubMed ID: 16707443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
    Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
    Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors.
    Mainwaring OJ; Weishaupt H; Zhao M; Rosén G; Borgenvik A; Breinschmid L; Verbaan AD; Richardson S; Thompson D; Clifford SC; Hill RM; Annusver K; Sundström A; Holmberg KO; Kasper M; Hutter S; Swartling FJ
    Nat Commun; 2023 Mar; 14(1):1221. PubMed ID: 36869047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells.
    Colvin Wanshura LE; Galvin KE; Ye H; Fernandez-Zapico ME; Wetmore C
    Cancer Res; 2011 Aug; 71(15):5336-45. PubMed ID: 21646478
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
    Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features.
    Leonard JR; Cai DX; Rivet DJ; Kaufman BA; Park TS; Levy BK; Perry A
    J Neurosurg; 2001 Jul; 95(1):82-8. PubMed ID: 11453402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
    Northcott PA; Fernandez-L A; Hagan JP; Ellison DW; Grajkowska W; Gillespie Y; Grundy R; Van Meter T; Rutka JT; Croce CM; Kenney AM; Taylor MD
    Cancer Res; 2009 Apr; 69(8):3249-55. PubMed ID: 19351822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth.
    Sengupta S; Weeraratne SD; Sun H; Phallen J; Rallapalli SK; Teider N; Kosaras B; Amani V; Pierre-Francois J; Tang Y; Nguyen B; Yu F; Schubert S; Balansay B; Mathios D; Lechpammer M; Archer TC; Tran P; Reimer RJ; Cook JM; Lim M; Jensen FE; Pomeroy SL; Cho YJ
    Acta Neuropathol; 2014 Apr; 127(4):593-603. PubMed ID: 24196163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia.
    Eberhart CG; Kratz J; Wang Y; Summers K; Stearns D; Cohen K; Dang CV; Burger PC
    J Neuropathol Exp Neurol; 2004 May; 63(5):441-9. PubMed ID: 15198123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants.
    Buss MC; Remke M; Lee J; Gandhi K; Schniederjan MJ; Kool M; Northcott PA; Pfister SM; Taylor MD; Castellino RC
    Oncogene; 2015 Feb; 34(9):1126-40. PubMed ID: 24632620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Proteogenomic Approach to Understanding MYC Function in Metastatic Medulloblastoma Tumors.
    Staal JA; Pei Y; Rood BR
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
    Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
    Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mouse model of the most aggressive subgroup of human medulloblastoma.
    Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF
    Cancer Cell; 2012 Feb; 21(2):168-80. PubMed ID: 22340591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
    Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
    Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations in mouse medulloblastomas and generation of tumors de novo from primary cerebellar granule neuron precursors.
    Zindy F; Uziel T; Ayrault O; Calabrese C; Valentine M; Rehg JE; Gilbertson RJ; Sherr CJ; Roussel MF
    Cancer Res; 2007 Mar; 67(6):2676-84. PubMed ID: 17363588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.